Office of Research & Development |
![]() ![]() |
Project Number: | I01BX003916-01A1 |
Title: | Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma |
Principal Investigator: | Mark R. Albertini |
Location: | Madison, WI |
Congressional District Code: | 2 |
Research Service: | Biomedical Laboratory R&D |
Project Period: | September 2019 - August 2023 |
FY 2021 Funding Amount: | $156,800 |
Total Award Amount (all years): |
$686,800 |
Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Malignant melanoma is a serious health issue for Veterans, and metastatic melanoma is usually incurable if it metastasizes to distant sites. Exciting and impressive data with immune checkpoint blockade demonstrate the ability of the immune system to produce durable responses in some metastatic melanoma patients and have changed the standard of care1. Effective treatment with immune checkpoint blockade seems to require activation of anti-melanoma T cells that are specific for a wide variety of me... |